Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 13;35:20587384211034686. doi: 10.1177/20587384211034686

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Cyclooxigeneas-2 inhibition evaluation. Effect of bromelain in preventing cyclooxigeneas-2 induction were detected through Enzyme Linked Immunosorbent Assay assay in Caco-2 (A), SW1353 (B) and AGS (C) cells. Histograms show the percentage of inhibition of cyclooxigeneas-2 expression respect to cells stimulated with TNF-α but without any bromelain treatment. Activity of cyclooxigeneas-2 in response to the inflammatory stimulus both in the absence and in the presence of bromelain at a concentration of 35 mg/L was reported for Caco-2 (D), SW1353 (E) and AGS (F) cells. Bromelain (bromelain untreated, control); Dig SGF (bromelain digested only in gastric fluid); Ctr SGF (SGF buffer without bromelain); Autodig (bromelain after autodigestion); Dig SGF+SIF (bromelain treated with gastrointestinal fluid); Ctr SGF+SIF (gastrointestinal fluid buffer without bromelain); Ketoprofene (Ketoprofene 142 μg/mL, positive control); ** p < 0.01; * p < 0.05.